Content about BOTHELL

January 7, 2011
Pfizer forms licensing agreement with Seattle Genetics

Pfizer has paid Seattle Genetics $8 million to license its antibody technology, Seattle Genetics said Thursday.

BOTHELL, Wash. — Pfizer has paid Seattle Genetics $8 million to license its antibody technology, Seattle Genetics said Thursday.

Seattle Genetics, based in Bothell, Wash., said Pfizer would pursue antibodies for treating an unspecified form of cancer using its antibody-drug conjugate technology. ADCs are monoclonal antibodies that selectively deliver anti-cancer agents to tumor cells. Seattle Genetics has developed anti-tumor drugs called auristatins, which are attached to antibodies and then used to kill the cancer cells while sparing noncancer cells.

September 29, 2010
Teva, OncoGenex commence phase-3 trial for advanced prostate cancer drug

Teva Pharmaceutical Industries and OncoGenex Pharmaceuticals have started a late-stage clinical trial of an investigative...

BOTHELL, Wash. Teva Pharmaceutical Industries and OncoGenex Pharmaceuticals have started a late-stage clinical trial of an investigative treatment for advanced prostate cancer, the two companies said Thursday.

 

Teva and OncoGenex, a company based in the Seattle suburb of Bothell, Wash., that develops cancer therapies, announced the start of “SYNERGY,” a phase-3 trial of OGX-011/TV-1011 (custirsen), a first-line therapy for treating castrate-resistant prostate cancer.

 

 

September 13, 2010
Seattle Genetics, Genmab to develop cancer therapeutics

Biotech companies Seattle Genetics and Genmab will collaborate to develop antibody treatments for cancer, the...

BOTHELL, Wash. Biotech companies Seattle Genetics and Genmab will collaborate to develop antibody treatments for cancer, the two companies announced Tuesday.

 

Seattle Genetics, based in the Seattle suburb of Bothell, Wash., and Denmark-based Genmab will develop the treatments using Seattle Genetics’ antibody-drug conjugate technology. Seattle Genetics received an undisclosed upfront payment and will have the right to exercise a co-development option for any products at the end of early-stage clinical development.